Literature DB >> 19096147

Potential biomarkers of colorectal adenoma-dysplasia-carcinoma progression: mRNA expression profiling and in situ protein detection on TMAs reveal 15 sequentially upregulated and 2 downregulated genes.

Orsolya Galamb1, Ferenc Sipos, Sándor Spisák, Barnabás Galamb, Tibor Krenács, Gábor Valcz, Zsolt Tulassay, Béla Molnár.   

Abstract

BACKGROUND: As most colorectal cancers (CRC) develop from villous adenomas, studying alterations in gene expression profiles across the colorectal adenoma-dysplasia-carcinoma sequence may yield potential biomarkers of disease progression.
METHODS: Total RNA was extracted, amplified, and biotinylated from colonic biopsies of 15 patients with CRC, 15 with villous adenoma and 8 normal controls. Gene expression profiles were evaluated using HGU133Plus2.0 microarrays and disease progression associated data were validated with RT-PCR. The potential biomarkers were also tested at the protein level using tissue microarray samples of 103 independent and 16 overlapping patients.
RESULTS: 17 genes were validated to show sequentially altered expression at mRNA level through the normal-adenoma-dysplasia-carcinoma progression. Prostaglandin-D2 receptor (PTGDR) and amnionless homolog (AMN) genes revealed gradually decreasing expression while the rest of 15 genes including osteonectin, osteopontin, collagen IV-alpha 1, biglycan, matrix GLAprotein, and von Willebrand factor demonstrated progressively increasing expression. Similar trends of expression were confirmed at protein level for PTGDR, AMN, osteopontin and osteonectin.
CONCLUSIONS: Downregulated AMN and PTGDR and upregulated osteopontin and osteonectin were found as potential biomarkers of colorectal carcinogenesis and disease progression to be utilized for prospective biopsy screening both at mRNA and protein levels. Gene alterations identified here may also add to our understanding of CRC progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19096147      PMCID: PMC4618585          DOI: 10.3233/clo-2009-0458

Source DB:  PubMed          Journal:  Cell Oncol        ISSN: 1570-5870            Impact factor:   6.730


  26 in total

1.  Elevated osteopontin expression and proliferative/apoptotic ratio in the colorectal adenoma-dysplasia-carcinoma sequence.

Authors:  Gábor Valcz; Ferenc Sipos; Tibor Krenács; Jeannette Molnár; Arpád V Patai; Katalin Leiszter; Kinga Tóth; Norbert Solymosi; Orsolya Galamb; Béla Molnár; Zsolt Tulassay
Journal:  Pathol Oncol Res       Date:  2010-03-27       Impact factor: 3.201

Review 2.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos
Journal:  Biochim Biophys Acta       Date:  2015-03-28

3.  Inhibition of versican expression by siRNA facilitates tropoelastin synthesis and elastic fiber formation by human SK-LMS-1 leiomyosarcoma smooth muscle cells in vitro and in vivo.

Authors:  Paul A Keire; Steven L Bressler; Eileen R Mulvihill; Barry C Starcher; Inkyung Kang; Thomas N Wight
Journal:  Matrix Biol       Date:  2015-12-23       Impact factor: 11.583

4.  Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer.

Authors:  Brigette L Tippin; A Joan Levine; Alicia M Materi; Wen-Liang Song; Temitope O Keku; Julie E Goodman; Leah B Sansbury; Sudipto Das; Aihua Dai; Alan M Kwong; Amy M Lin; John M Lin; Jae Man Park; Ruth E Patterson; Rowan T Chlebowski; R Michael Garavito; Tsuyoshi Inoue; Wonhwa Cho; John A Lawson; Shiv Kapoor; Laurence N Kolonel; Loïc Le Marchand; Robert W Haile; Robert S Sandler; Henry J Lin
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-07-28       Impact factor: 3.072

Review 5.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

6.  Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers.

Authors:  Xiaohu Gu; Yegang Ma; Jingdong Xiao; Hongxin Zheng; Chun Song; Yuehua Gong; Xiaojing Xing
Journal:  Clin Exp Med       Date:  2011-08-31       Impact factor: 3.984

7.  Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors.

Authors:  Michal Mikula; Tymon Rubel; Jakub Karczmarski; Krzysztof Goryca; Michal Dadlez; Jerzy Ostrowski
Journal:  Funct Integr Genomics       Date:  2010-11-09       Impact factor: 3.410

Review 8.  Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer.

Authors:  M T M van Jaarsveld; J M Houthuijzen; E E Voest
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

9.  High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Ying-Hui Zhu; Fu Yang; Shui-Shen Zhang; Ting-Ting Zeng; Xuan Xie; Xin-Yuan Guan
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

10.  Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor.

Authors:  O Galamb; S Spisák; F Sipos; K Tóth; N Solymosi; B Wichmann; T Krenács; G Valcz; Z Tulassay; B Molnár
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.